Key facts
- Notable investors include Ripple Ventures, Defined, Velocity (Consulting Services (B2B)).
- Status: Privately Held (backing).
- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for Zeroshot bio
- ·The full record, as it builds
Funding rounds
No funding rounds for Zeroshot bio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Zeroshot bio
Developer of a generative AI-based molecular design tool intended for drug discovery and optimization purposes. The company's platform integrates large language models with molecular simulation and active learning workflows, enabling pharmaceutical and biotech researchers to rapidly generate, evaluate, and prioritize novel compounds with desired properties across multiple therapeutic targets, while reducing experimental overhead and accelerating early-stage development timelines.
- Sector
- Healthcare
- HQ
- Vancouver, Canada
- Founded
- 2025
- Employees
- 3
- Website
- zeroshot.bio/
- Ownership
- Privately Held (backing)
Zeroshot bio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Zeroshot bio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Zeroshot bio in its N-PORT filings yet. We sweep new filings monthly.